RAS-PIK3CA inhibitor therapy(Vividion Therapeutics)

N/A

Report date: 2024/11/08 15:38:37
NME

Base Information

Drug NameRAS-PIK3CA inhibitor therapy(Vividion Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaN/A
Originator CompaniesVividion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVividion Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A